🇺🇸 FDA
Patent

US 10350228

Treatment of sickle cell disease and inflammatory conditions

granted A61KA61K31/7004A61K31/7024

Quick answer

US patent 10350228 (Treatment of sickle cell disease and inflammatory conditions) held by Regents of the University of Minnesota expires Mon Jul 11 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Regents of the University of Minnesota
Grant date
Tue Jul 16 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 11 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61K, A61K31/7004, A61K31/7024, A61K31/7048, A61P